In addition, we report the results of translational research in an attempt to unravel the mechanisms of action (MOAs) of olverembatinib in patients with SDH-deficient GIST, which included clinical biomarker analysis, in vitro and ex vivo studies in several other SDH-deficient tumor cell lines (due to the paucity of preclinical models of SDH-deficient GIST), and primary SDH-deficient GIST cells freshly isolated from patient biopsies. This evidence concerns the gene SDHB and gastrointestinal stromal tumor.